153 related articles for article (PubMed ID: 27211906)
21. Bcl-2 and CCND1/CDK4 expression levels predict the cellular effects of mTOR inhibitors in human ovarian carcinoma.
Aguirre D; Boya P; Bellet D; Faivre S; Troalen F; Benard J; Saulnier P; Hopkins-Donaldson S; Zangemeister-Wittke U; Kroemer G; Raymond E
Apoptosis; 2004 Nov; 9(6):797-805. PubMed ID: 15505422
[TBL] [Abstract][Full Text] [Related]
22. Concurrent inhibition of PI3K and mTORC1/mTORC2 overcomes resistance to rapamycin induced apoptosis by down-regulation of Mcl-1 in mantle cell lymphoma.
Müller A; Zang C; Chumduri C; Dörken B; Daniel PT; Scholz CW
Int J Cancer; 2013 Oct; 133(8):1813-24. PubMed ID: 23580240
[TBL] [Abstract][Full Text] [Related]
23. Targeting Focal Adhesion Kinase and Resistance to mTOR Inhibition in Pancreatic Neuroendocrine Tumors.
François RA; Maeng K; Nawab A; Kaye FJ; Hochwald SN; Zajac-Kaye M
J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 25971297
[TBL] [Abstract][Full Text] [Related]
24. Asiatic acid exerts anticancer potential in human ovarian cancer cells via suppression of PI3K/Akt/mTOR signalling.
Ren L; Cao QX; Zhai FR; Yang SQ; Zhang HX
Pharm Biol; 2016 Nov; 54(11):2377-2382. PubMed ID: 26984021
[TBL] [Abstract][Full Text] [Related]
25. Rapamycin enhanced the antitumor efficacy of oxaliplatin in cisplatin-resistant ovarian cancer cells A2780cis both in vitro and in vivo.
Liu J; Zhang L; Zhang X; Xing X
J Chemother; 2015; 27(6):358-64. PubMed ID: 25976336
[TBL] [Abstract][Full Text] [Related]
26. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.
deGraffenried LA; Friedrichs WE; Russell DH; Donzis EJ; Middleton AK; Silva JM; Roth RA; Hidalgo M
Clin Cancer Res; 2004 Dec; 10(23):8059-67. PubMed ID: 15585641
[TBL] [Abstract][Full Text] [Related]
28. Effects of a combined treatment with mTOR inhibitor RAD001 and tamoxifen in vitro on growth and apoptosis of human cancer cells.
Treeck O; Wackwitz B; Haus U; Ortmann O
Gynecol Oncol; 2006 Aug; 102(2):292-9. PubMed ID: 16443261
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 in a preclinical model of adrenocortical carcinoma.
Doghman M; Lalli E
Mol Cell Endocrinol; 2012 Nov; 364(1-2):101-4. PubMed ID: 22960230
[TBL] [Abstract][Full Text] [Related]
30. mTOR regulate EMT through RhoA and Rac1 pathway in prostate cancer.
Chen X; Cheng H; Pan T; Liu Y; Su Y; Ren C; Huang D; Zha X; Liang C
Mol Carcinog; 2015 Oct; 54(10):1086-95. PubMed ID: 25043657
[TBL] [Abstract][Full Text] [Related]
31. The dual PI3K and mTOR inhibitor NVP-BEZ235 exhibits anti-proliferative activity and overcomes bortezomib resistance in mantle cell lymphoma cells.
Kim A; Park S; Lee JE; Jang WS; Lee SJ; Kang HJ; Lee SS
Leuk Res; 2012 Jul; 36(7):912-20. PubMed ID: 22560334
[TBL] [Abstract][Full Text] [Related]
32. MT-4 suppresses resistant ovarian cancer growth through targeting tubulin and HSP27.
Pai HC; Kumar S; Shen CC; Liou JP; Pan SL; Teng CM
PLoS One; 2015; 10(4):e0123819. PubMed ID: 25874627
[TBL] [Abstract][Full Text] [Related]
33. Promise of rapalogues versus mTOR kinase inhibitors in subset specific breast cancer: old targets new hope.
De P; Miskimins K; Dey N; Leyland-Jones B
Cancer Treat Rev; 2013 Aug; 39(5):403-12. PubMed ID: 23352077
[TBL] [Abstract][Full Text] [Related]
34. Concurrent inhibition of PI3-kinase and mTOR induces cell death in diffuse large B cell lymphomas, a mechanism involving down regulation of Mcl-1.
Zang C; Eucker J; Liu H; Müller A; Possinger K; Scholz CW
Cancer Lett; 2013 Oct; 339(2):288-97. PubMed ID: 23200668
[TBL] [Abstract][Full Text] [Related]
35. Human cytomegalovirus infection alters the substrate specificities and rapamycin sensitivities of raptor- and rictor-containing complexes.
Kudchodkar SB; Yu Y; Maguire TG; Alwine JC
Proc Natl Acad Sci U S A; 2006 Sep; 103(38):14182-7. PubMed ID: 16959881
[TBL] [Abstract][Full Text] [Related]
36. Targeting mTOR signaling pathway in ovarian cancer.
Mabuchi S; Hisamatsu T; Kimura T
Curr Med Chem; 2011; 18(19):2960-8. PubMed ID: 21651485
[TBL] [Abstract][Full Text] [Related]
37. Grifolin induces autophagic cell death by inhibiting the Akt/mTOR/S6K pathway in human ovarian cancer cells.
Che X; Yan H; Sun H; Dongol S; Wang Y; Lv Q; Jiang J
Oncol Rep; 2016 Aug; 36(2):1041-7. PubMed ID: 27277722
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of dual PI-3K and mTOR inhibitors in vitro and in vivo in acute lymphoblastic leukemia.
Wong J; Welschinger R; Hewson J; Bradstock KF; Bendall LJ
Oncotarget; 2014 Nov; 5(21):10460-72. PubMed ID: 25361005
[TBL] [Abstract][Full Text] [Related]
39. mTOR in renal cell cancer: modulator of tumor biology and therapeutic target.
Wysocki PJ
Expert Rev Mol Diagn; 2009 Apr; 9(3):231-41. PubMed ID: 19379082
[TBL] [Abstract][Full Text] [Related]
40. The novel dual PI3K/mTOR inhibitor NVP-BGT226 displays cytotoxic activity in both normoxic and hypoxic hepatocarcinoma cells.
Simioni C; Cani A; Martelli AM; Zauli G; Alameen AA; Ultimo S; Tabellini G; McCubrey JA; Capitani S; Neri LM
Oncotarget; 2015 Jul; 6(19):17147-60. PubMed ID: 26003166
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
